CTLA4 and metastatic melanoma: Bacteria belonging to the Bacteroidetes phylum have been demonstrated to be protective against the development of ICI-related colitis in metastatic melanoma patients treated with anti-CTLA-4 (57, 58), though possibly correlating with a poorer oncological outcome (57).